RPTX241220P7500
- 4.39
- 0.000.00%
Repare Therapeutics Newsroom
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Cuts Target Price to $6
Piper Sandler Sticks to Its Buy Rating for Repare Therapeutics (RPTX)
Express News | Repare Therapeutics Inc : Piper Sandler Cuts Target Price to $6 From $25
Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX) and Centene (CNC)
Institutional Investors May Adopt Severe Steps After Repare Therapeutics Inc.'s (NASDAQ:RPTX) Latest 44% Drop Adds to a Year Losses
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Hold Rating on Repare Therapeutics Amid Mixed Trial Results and Anemia Concerns
Curative CUBT +52% Strategic Advisor; Repare Therapeutics RPTX -55% Phase 1 Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
Express News | LifeSci Capital Downgrades Repare Therapeutics to Market Perform
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
Top Midday Decliners
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast
Why Is Repare Therapeutics Stock Trading Lower On Friday?
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results
US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings
Express News | Repare Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down - 47.4%
Wall Street Set to Open Higher Friday as Investors Shake Off Bad Week
Repare Therapeutics Reports Positive Data From MYTHIC Phase 1 Trial And Plans For Phase 3 In 2025
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Eye Third Rate Cut